Utilize este identificador para referenciar este registo:
http://hdl.handle.net/10451/51497| Título: | July 2017 ENCALS statement on edaravone |
| Autor: | Al-Chalabi, Ammar Andersen, Peter M. Chandran, Siddharthan Chio, Adriano Corcia, Philippe Couratier, Philippe Danielsson, Olof Carvalho, Mamede Desnuelle, Claude Grehl, Torsten Grosskreutz, Julian Holmøy, Trygve Ingre, Caroline Karlsborg, Merete Kleveland, Grethe Christoph Koch, Jan Koritnik, Blaz KuzmaKozakiewicz, Magdalena Laaksovirta, Hannu Ludolph, Albert McDermott, Christopher Meyer, Thomas Mitre Ropero, Bernardo Mora Pardina, Jesus Nygren, Ingela Petri, Susanne Povedano Panades, Mónica Salachas, Francois Shaw, Pamela Silani, Vincenzo Staaf, Gert Svenstrup, Kirsten Talbot, Kevin Tysnes, Ole-Bjørn Van Damme, Philip van der Kooi, Anneke Weber, Markus Weydt, Patrick Wolf, Joachim Hardiman, Orla van den Berg, Leonard H. |
| Data: | 2017 |
| Editora: | Taylor & Francis |
| Citação: | Amyotroph Lateral Scler Frontotemporal Degener. 2017 Nov;18(7-8):471-474 |
| Resumo: | Neurologists of the ENCALS centers throughout Europe have discussed the potential of edaravone as a new therapy for amyotrophic lateral sclerosis (ALS, Motor Neuron Disease, MND) at the ENCALS meeting, 18–20 May 2017, in Ljubljana, Slovenia. In May 2017, the US Food and Drug Administration (FDA) granted a license for the drug known as edaravone (licensed in Japan in 2015 as Radicut) for the treatment of ALS in the United States (to be marketed as Radicava). We are not aware of any official request from Mitsubishi Tanabe Pharma, the manufacturer of edaravone, to the European Medicines Agency (EMA) to register the drug for use in ALS in Europe. However, edaravone can be imported to Europe from Japan or the United States. |
| Descrição: | © 2017 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. |
| Peer review: | yes |
| URI: | http://hdl.handle.net/10451/51497 |
| DOI: | 10.1080/21678421.2017.1369125 |
| ISSN: | 2167-8421 |
| Versão do Editor: | https://www.tandfonline.com/journals/iafd20 |
| Aparece nas colecções: | FM - Artigos em Revistas Internacionais IMM - Artigos em Revistas Internacionais |
Ficheiros deste registo:
| Ficheiro | Descrição | Tamanho | Formato | |
|---|---|---|---|---|
| July_2017.pdf | 1,08 MB | Adobe PDF | Ver/Abrir |
Todos os registos no repositório estão protegidos por leis de copyright, com todos os direitos reservados.
